Literature DB >> 6418388

Antibodies to plasminogen activator inhibit human tumor metastasis.

L Ossowski, E Reich.   

Abstract

The human carcinoma HEp3 grows on the chorioallantoic membrane and metastasizes to the chicken embryo with kinetics that are quantitatively predictable. We have used this experimental system to test whether plasminogen activator produced by the tumor is required for metastasis. Rabbit antibodies were raised against human urinary urokinase; these cross-reacted with and blocked the catalytic activity of HEp3-PA but did not inhibit chicken PA. When administered intravenously to embryos that had received an inoculum of HEp3 cells, the anti-urokinase antibodies did not inhibit tumor growth at the site of primary inoculation on the chorioallantoic membrane, but they either prevented or strongly inhibited metastasis to the embryo lung. Antibody treatment delayed the onset of pulmonary metastasis, indicating that plasminogen activator is required during early stages of the process.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6418388     DOI: 10.1016/0092-8674(83)90093-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  129 in total

1.  Migration of keratinocytes through tunnels of digested fibrin.

Authors:  V Ronfard; Y Barrandon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

3.  Integrin expression in human melanoma cells with differing invasive and metastatic properties.

Authors:  K R Gehlsen; G E Davis; P Sriramarao
Journal:  Clin Exp Metastasis       Date:  1992-03       Impact factor: 5.150

Review 4.  Cell-matrix interactions during tumor invasion.

Authors:  J R Starkey
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

5.  Transforming growth factor-ßs as modulators of pericellular proteolytic events.

Authors:  J Keski-Oja; J Lohi; M Laiho
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

6.  Identification of a plasminogen activator derived from nasopharyngeal carcinoma.

Authors:  T Kosugi; G W Huang; M Nakamura; S Koja; H T Nong
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

7.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

Review 8.  Role of plasma, platelets, and endothelial cells in tumor metastasis.

Authors:  G J Gasic
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

9.  Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.

Authors:  U Reuning; O Wilhelm; T Nishiguchi; L Guerrini; F Blasi; H Graeff; M Schmitt
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

10.  Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.

Authors:  Takuya Akai; Kenji Niiya; Nobuo Sakuragawa; Hideaki Iizuka; Shunro Endo
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.